Mean (SD) | 95%-CI | Minimum | Maximum | |
---|---|---|---|---|
Etanercept (n = 233) | ||||
Outpatient care | 4 (11) | 3-6 | 0 | 164 |
Medications | 83 (20) | 80-86 | 62 | 301 |
Laboratory tests | 2 (2) | 2-2 | 0 | 18 |
Ambulatory care in hospitals | 1 (3) | 1-1 | 0 | 18 |
Devices and aids | 0 (1) | 0-0 | 0 | 5 |
Other claims | 2 (7) | 1-3 | 0 | 95 |
Total daily cost (etanercept) | 92 (26) | 89-96 | 69 | 328 |
Adalimumab (n = 201) | ||||
Outpatient care | 4 (4) | 4-5 | 0 | 22 |
Medications | 84 (12) | 82-86 | 65 | 159 |
Laboratory tests | 2 (2) | 2-2 | 0 | 21 |
Ambulatory care in hospitals | 1 (3) | 1-2 | 0 | 17 |
Devices and aids | 0 (1) | 0-0 | 0 | 11 |
Other claims | 1 (3) | 1-2 | 0 | 29 |
Total daily cost (adalimumab) | 93 (14) | 91-95 | 68 | 169 |
Infliximab (n = 121) | ||||
Outpatient care | 4 (5) | 3-4 | 0 | 25 |
Medications | 118 (84) | 103-133 | 36 | 823 |
Laboratory tests | 3 (3) | 3-4 | 0 | 17 |
Ambulatory care in hospitals | 9 (9) | 7-10 | 0 | 65 |
Devices and aids | 1 (1) | 0-1 | 0 | 4 |
Other claims | 1 (2) | 0-1 | 0 | 12 |
Total daily cost (infliximab) | 135 (88) | 119-151 | 63 | 878 |